EP12.01-20 Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)

The EGFRex20ins mutation is a significant driver mutation in non-small cell lung cancer (NSCLC), despite its relative rarity. This mutation is known to be less sensitive to approved EGFR tyrosine kinase inhibitors (TKI). Platinum-based doublet chemotherapy is used as a first-line treatment. Amivantamab is a fully humanized, bispecific IgG1 antibody that targets both EGFR and c-MET receptors with immune cell-directing activity. The Chrysalis-phase I study demonstrated the high efficacy of amivantamab in pre-treated patients with EGFRex20ins (ORR: 43%).